Aceas Abivertinib is a late stage drug that has shown positive clinical trial results in non-small cell lung cancer and B-Cell Lymphoma. Earlier this month, the company announced completion of the Acea Therapeutics acquisition. The drugmaker said it had responded to the U.S. agencys request for additional details on the benefit-risk profile of the drug, adding the FDA would require additional time for a full review of the application. The drugmaker said it had responded to the U.S. agency's request for additional details on the benefit-risk profile of the drug, adding the FDA would require additional time for a full review of the application. If successful, Sorrento will look for regulatory approvals in other countries as well.
The FDA completed the original terms of the competence followed such phases:
( z0 follow :ARG1 ( z1 phase :mod ( z2 such ) ) :ARG2 ( z3 complete :ARG0 ( z4 government-organization :name ( z5 name :op "FDA" ) ) :ARG1 ( z6 term :mod ( z7 original ) :poss ( z8 competence ) ) ) )
(z0 / follow-01
    :ARG1 (z1 / phase
              :mod (z2 / such))
    :ARG2 (z3 / complete-01
              :ARG0 (z4 / government-organization
                        :name (z5 / name
                                  :op1 "FDA"))
              :ARG1 (z6 / term
                        :mod (z7 / original)
                        :poss (z8 / competence))))
The FDA completed the original terms of the competence followed such phases :
z4 :name z5
z5 :op1 0
z3 :ARG0 z4
z6 :mod z7
z3 :ARG1 z6
z6 :poss z8
z0 :ARG2 z3
z1 :mod z2
z0 :ARG1 z1